

E Number	Hits	Search Text	DB	Time stamp
1	97	Sheppard NEAR Michael	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/05/24 15:07
2	3	(Sheppard NEAR Michael) and endostatin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/05/24 15:07
4	11	Tong NEAR Xiao	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/05/24 15:08
5	1712	endostatin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/05/24 15:08
7	7	endostatin SAME (cani\$3 or dog)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/05/24 15:10
8	7	(US-20030139365-\$ or US-20030158099-\$ or US-20030059417-\$).did. or (EP-1197550-\$ or EP-1191036-\$).did. or (JP-2003000268-\$ or JP-2002355056-\$).did.	US-PGPUB; EPO; JPO	2004/05/24 15:11
-	2	"20030139365"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/15 14:47
-	55	Gillies NEAR Stephen	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/15 14:54

=> d his

(FILE 'HOME' ENTERED AT 15:11:43 ON 24 MAY 2004)

FILE 'MEDLINE, CAPLUS' ENTERED AT 15:12:01 ON 24 MAY 2004

L1 3 S ENDOSTATIN (L) (CANI? OR DOG)
L2 3 DUP REM L1 (0 DUPLICATES REMOVED)
E SPEPPARD MICHAEL?/AU
E SHEPPARD MICHAEL?/AU
L3 9 S E1

=> d an ti so au ab pi l2 l-3

L2 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:237903 CAPLUS
DN 136:259025
TI cDNA encoding **endostatin** and its use as inhibitor of cancer and
angiogenesis-related disorders in **dogs**
SO Eur. Pat. Appl., 56 pp.
CODEN: EPXXDW
IN Sheppard, Michael G.; Tong, Xiao
AB The present invention relates to **canine endostatin**
genes and polypeptides associated as inhibitors of angiogenesis-related
disorders, such as cancer. The invention encompasses **endostatin**
nucleic acids, recombinant DNA mols., cloned genes or degenerate variants
thereof, **endostatin** gene products and antibodies directed
against such gene products, cloning vectors containing mammalian
endostatin gene mols., and hosts that have been genetically
engineered to express such mols. In a further embodiment the said
endostatin is not from chicken, human or mouse. The invention
further relates to methods for the identification of compds. that modulate
the expression of **endostatin** genes and gene products and to
using such compds. as therapeutic agents in the treatment of
angiogenesis-related disorders, e.g., cancer. The invention also relates
to methods for the diagnostic evaluation, genetic testing and prognosis of
angiogenesis-related disorders, e.g., cancer, and to methods and compns.
for the treatment these disorders. Angiogenesis-related disorders include
angiogenesis-dependent cancers comprising solid tumors and blood borne
tumors such as leukemias, tumor metastases, benign tumors comprising
hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic
granulomas. Also included are rheumatoid arthritis, psoriasis, ocular
angiogenic diseases comprising diabetic retinopathy, retinopathy of
prematurity, macular degeneration, corneal graft rejection, neo-vascular
glaucoma, retrolental fibroplasia, and rubeosis. Osler-Webber syndrome,
myocardial angiogenesis, plaque neovascularization, telangiectasia,
hemophiliac joints, angiofibroma, wound granulation, coronary collaterals,
cerebral collaterals, and arteriovenous malformations are also included.
Other diseases include ischemic limb angiogenesis, diabetic
neovascularization, macular degeneration, fractures, vasculogenesis,
hematopoiesis, ovulation, menstruation and placentation.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1191036	A2	20020327	EP 2001-307224	20010824
EP 1191036	A3	20020703		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003000268	A2	20030107	JP 2001-254697	20010824
US 2003158099	A1	20030821	US 2001-938391	20010824

L2 ANSWER 2 OF 3 MEDLINE on STN
AN 2002487981 MEDLINE
TI **Endostatin** concentrations in healthy **dogs** and
dogs with selected neoplasms.
SO Journal of veterinary internal medicine / American College of Veterinary
Internal Medicine, (2002 Sep-Oct) 16 (5) 565-9.
Journal code: 8708660. ISSN: 0891-6640.
AU Rossmeisl John H Jr; Bright Patricia; Tamarkin Lawrence; Simpson Byron W;
Troy Gregory C; Hueston William; Ward Daniel L
AB **Endostatin** prevents angiogenesis and tumor growth by inhibiting

endothelial cell proliferation and migration. The purpose of this study was to determine serum **endostatin** concentrations in 53 healthy **dogs** and in 38 **dogs** with confirmed malignant neoplasms. **Endostatin** concentration was determined with a competitive enzymatic immunoassay (EIA) with rabbit polyclonal antibody generated against a recombinant **canine endostatin** protein. Both the presence of cancer and increasing age were associated with increased serum concentration of **endostatin**. **Endostatin** concentration in healthy **dogs** was 87.7 +/- 3.5 ng/mL. Upper and lower limits of the reference range for serum **endostatin** concentration in healthy **dogs** were 60 and 113 ng/mL. **Dogs** with lymphoma (LSA) and hemangiosarcoma (HSA) had **endostatin** concentrations of 107 +/- 9.3 ng/mL. In conclusion, this study demonstrates that **endostatin** can be quantified in **dogs** and that **endostatin** concentrations are high in **dogs** with HSA and LSA.

L2 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:144909 CAPLUS

DN 132:190503

TI Expression and export of angiostatin and endostatin as immunofusins

SO PCT Int. Appl., 68 pp.

CODEN: PIXXD2

IN Lo, Kin-Ming; Li, Yue; Gillies, Stephen D.

AB Disclosed are nucleotide sequences, for example, DNA or RNA sequences, which encode an Ig Fc-angiogenesis inhibitor fusion protein. The angiogenesis inhibitors can be angiostatin, endostatin, a plasminogen fragment having angiostatin activity, or a collagen XVIII fragment having endostatin activity. The nucleotide sequences can be inserted into a suitable expression vector and expressed in mammalian cells. Also disclosed is a family of Ig Fc-angiogenesis inhibitor fusion proteins that can be produced by expression of such nucleotide sequences. Also disclosed are methods using such nucleotide sequences and fusion proteins for treating conditions mediated by angiogenesis. When C57/BL6 mice with implanted Lewis lung tumors are injected with 720 µg human Fc-human angiostatin fusion protein per mouse, the protein had a circulating half-life of about 32 h, and Western anal. shows that >90% of the fusion protein remains as an intact mol. in circulation.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO 2000011033	A2	20000302	WO 1999-US19329	19990825
----	---------------	----	----------	-----------------	----------

	WO 2000011033	A3	20000622		
--	---------------	----	----------	--	--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2339331	AA	20000302	CA 1999-2339331	19990825
------------	----	----------	-----------------	----------

AU 9955836	A1	20000314	AU 1999-55836	19990825
------------	----	----------	---------------	----------

AU 761027	B2	20030529		
-----------	----	----------	--	--

BR 9913331	A	20010515	BR 1999-13331	19990825
------------	---	----------	---------------	----------

EP 1107989	A2	20010620	EP 1999-942468	19990825
------------	----	----------	----------------	----------


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2002523036	T2	20020730	JP 2000-566305	19990825
---------------	----	----------	----------------	----------

ZA 2001001290	A	20020215	ZA 2001-1290	20010215
---------------	---	----------	--------------	----------

NO 2001000918	A	20010419	NO 2001-918	20010223
---------------	---	----------	-------------	----------

US 2003139365	A1	20030724	US 2002-292418	20021112
---------------	----	----------	----------------	----------



Books

Go Clear

Details

Display: default Show: 20 Send to: File Get Subsequence Features

Links

ORIGIN

1	ccttggcggg	cagatgacat	cctggcgggc	ccccgcggcc	tgttggaacc	cagccctac
61	cccggggccc	cgaccacgg	ctctacgtg	catttcacg	cggctcgccc	cactggtggg
121	ccgtccaca	cccacaccca	caccaccag	gacttcacg	tgggtctgtca	cctggtggcc
181	ctgaacagcc	cgcagcggg	cggcatgcga	ggcatccgg	gagcggactt	cagtgcttc
241	cagcaggcgc	gcgcgcggg	cgtggcggc	acctccggg	ccttcctgtc	gtcgcggctg
301	caggacctct	acagcatcgt	gcgcgcggc	gaccgcaccg	gggtgcccg	cgtcaacctc
361	agggacgagg	tgtctttccc	cagctgggag	gccttattct	cgggctccga	gggccagctg
421	aagccccggg	ccgcgactct	ctcttctgac	ggcagagatg	tcttcgagca	ccccgcctgg
481	ccccggaaga	gcgtgtggca	cgtctccgac	ccagcgggc	gcgcgctgac	gcagacgtac
541	tgcgagacgt	ggcggacgga	ggccccggcg	gccaccggcg	aggcgtcgtc	gctgctggcg
601	ggcaggctgc	tggagcagga	ggccgcgagc	tgccgccacg	ccttcgtggt	gctctgcata
661	gagaacagcg	tcatgcacct	cttctccaag	tagggccggc	cggccacgga	acaggcgggg
721	gaggggggcg	ccgcaggagc	atccgcggcc	cgggggggcg	ctggccggga	cgttgctgtg
781	caccgtcacg	tttaattgtaa	tctcaagaa	ataaaaggaa	qccaaaagaa	

[Disclaimer](#) | [Write to the Help Desk](#)
NCBI | NLM | NIH

May 12 2004 07:05:19



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Books

Search for

Limits

Preview/Index

History

Clipboard

Details

☐ 1: AX399631. Sequence 3 from P...[gi:21335410]

[Links](#)

LOCUS AX399631 555 bp DNA linear PAT 06-JUN-2002

DEFINITION Sequence 3 from Patent EP1191036.

ACCESSION AX399631

VERSION AX399631.1 GI:21335410

KEYWORDS

SOURCE Canis familiaris (dog)

ORGANISM Canis familiaris

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.

REFERENCE 1

AUTHORS Sheppard,M.G. and Tong,X.

TITLE Methods and compositions for diagnosing and treating disorders
involving angiogenesis

JOURNAL Patent: EP 1191036-A 3 27-MAR-2002;
Pfizer Products Inc. (US)

FEATURES

Location/Qualifiers

source 1..555

/organism="Canis familiaris"

/mol_type="unassigned DNA"

/db_xref="taxon:9615"

ORIGIN

```
1 cacacccacc aggacttcca gctggtgctg cacctggtgg ccttgaacag cccgcagccg
61 ggcggcacgc gaggcatccg gggagcggac ttccagtgtc tccagcaggc gcgcgcgcgc
121 gggtctggccg gcaccttccg ggccttctct tgcgtcgcgc tgcaggacct ctacagcatc
181 gtgcgcgcgc cgcaccgcac cggggtgccc gtcgtcaacc tcagggaaga ggtgctcttc
241 cccagctggg aggccttatt ctcgggctcc gagggccagc tgaagcccg ggcccgcatc
301 ttctcttttc acggcagaga tgcctgcag caccctgcct ggccccggaa gacggtgtgg
361 cagggtcccg accccagcgg gcgcgcctg accgacagct actgcgagac gtggcggacg
421 gagggcccg cgccaccgg gcaggcgtcg tgcgtgctgg cgggcaggct gctggagcag
481 gagggcgcga gctgcgcga cgccttcgtg gtgctctgca tcgagaacag cgtcatgacc
541 tccttctcca agtag
```

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

May 12 2004 07:05:19